Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

IONETIX Corporation Expands Lansing, Michigan, Operations

06/05/2025
Biotechnology company IONETIX Corporation plans to expand its operations in Lansing, Michigan. The $25.75 million project is expected to create 53 new jobs.

The investment will include the renovation, improvement, and expansion at the company’s existing locations which will increase supply chain distribution of its radiopharmaceutical products.

"Delta Township and the Lansing region offer the ideal environment for IONETIX’s continued growth. The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion,” said Kevin J. Cameron, Chief Executive Officer of IONETIX. “We are honored to invest in this community and proud that it is at the forefront of creating diagnostic and therapeutic innovations.”

The project is being supported by a $750,000 Michigan Business Development Program performance-based grant.

"We are thrilled with the company’s commitment to Michigan and the Lansing community by investing over $25 million to accelerate the efforts to one day cure cancer,” noted Matt McCauley, Senior Vice President for Regional Development at the Michigan Economic Development Corporation (MEDC). "Team Michigan welcomes IONETIX Corporation’s expansion, furthering Michigan’s leadership in the life sciences and medical technology industries. We applaud the company’s vision to Make it in Michigan."

In addition to MSF support, LEAP has put forward a tailored suite of support that includes funding from the Michigan New Jobs Training Program as well as a Michigan Works! proposal for training and workforce support.

“IONETIX’s investment demonstrates Michigan’s emerging leadership in the high-growth radiopharmaceutical and nuclear medicine sectors,” added Bob Trezise, president and CEO of the Lansing Economic Area Partnership (LEAP). “This expansion is not only creating high-wage, future-forward jobs—it’s solidifying Michigan’s position as a hub for advanced biomedical research, innovation, and manufacturing. We’re proud to partner with IONETIX, the MEDC and Delta Township to support this transformative project with global impact.”

IONETIX Corporation focuses on developing and commercializing radiopharmaceuticals for medical imaging and cancer treatment, particularly with a focus on N-13 Ammonia for cardiac PET imaging. The company also works in targeted alpha therapy (TAT) using alpha radionuclides.

Exclusive Research